Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Mari Fukushima-Shintani"'
Autor:
Tomihisa Kawasaki, Masaki Abe, Fukushi Hirayama, Ken-ichi Suzuki, Mari Fukushima-Shintani, Yoshiyuki Iwatsuki, Keizo Sugasawa
Publikováno v:
Experimental Hematology. 36:1337-1342
Objective AKR-501 (YM477) is an orally active thrombopoietin (TPO) receptor agonist that mimics the biological effect of TPO in vitro and in vivo. Here, we report that AKR-501 in combination with TPO has additive effect on megakaryocytopoiesis. Mater
Autor:
Keizo Sugasawa, Ken-ichi Suzuki, Fukushi Hirayama, Tomihisa Kawasaki, Yoshiyuki Iwatsuki, Tatsutoshi Nakahata, Mari Fukushima-Shintani, Masaki Abe
Publikováno v:
European journal of haematology. 82(4)
Thrombopoietin (TPO) is the principal physiologic regulator of platelet production. We have searched for small molecule compounds that mimic the action of TPO by using human TPO receptor-expressed in Ba/F3 cells, resulting in the discovery of AKR-501
Autor:
Hidefumi Hiramatsu, Mari Fukushima-Shintani, Tatsutoshi Nakahata, Toshio Heike, Ken-ichi Suzuki
Publikováno v:
European Journal of Haematology. :061114074547003
A suitable model for the preclinical study of human platelet production in vivo has not been available. NOD/SCID mice were characterized as representing an efficient engraftment model for human hematopoietic stem cells, which resulted in the producti
Autor:
Hidefumi Hiramatsu, Tatsutoshi Nakahata, Tomihisa Kawasaki, Mari Fukushima-Shintani, Masaki Abe, Fukushi Hirayama, Keizo Sugasawa, Ken-ichi Suzuki
Publikováno v:
Blood. 106:2298-2298
Thrombopoietin (TPO) is the principal physiologic regulator of platelet production. The search for an orally-active nonpeptidyl small molecule TPO receptor agonist has resulted in the discovery of YM477. YM477 acted specifically on the TPO receptor a